Expertise in
13
conditions

Dr. Mark Roschewski

Hematology
Office
7707 Wisconsin Ave Apt 1106, 
Bethesda, MD 
Clinical Trials:Currently Recruiting for 5 Trials
Expertise in
13
conditions
Office
7707 Wisconsin Ave Apt 1106, 
Bethesda, MD 

Overview

Mark Roschewski is a Hematologist in Bethesda, Maryland. Dr. Roschewski is highly rated in 13 conditions, according to our data. His top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Smoldering Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), and Vitrectomy.

His clinical research consists of co-authoring 126 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Hematology

Licenses

Internal Medicine in AK

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Office
7707 Wisconsin Ave Apt 1106, Bethesda, MD 20814

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (TEDDI-R) in Primary CNS Lymphoma
Enrollment Status: Recruiting
Publish Date: January 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Isavuconazole, TEDDI, Rituximab, Cytarabine, TEDD, Ibrutinib
Study Phase: Phase 1
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Phase 2 Trial of Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-Hodgkin Lymphomas
Enrollment Status: Recruiting
Publish Date: January 16, 2026
Intervention Type: Biological
Study Drug: Nivolumab
Study Phase: Phase 2
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol
Enrollment Status: Recruiting
Publish Date: January 09, 2026
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
A Phase 2 Study of Acalabrutinib With DA-EPOCH-R or R-CHOP for Patients With Untreated Diffuse Large B-cell Lymphoma
Enrollment Status: Recruiting
Publish Date: January 08, 2026
Intervention Type: Biological, Drug
Study Drugs: DA-EPOCH, Rituximab, CHOP, Acalabrutinib
Study Phase: Phase 2
Prospective Study of Clonal Evolution in Follicular Lymphoma
Prospective Study of Clonal Evolution in Follicular Lymphoma
Enrollment Status: Recruiting
Publish Date: December 18, 2025
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DKd) in Patients With High-Risk Smoldering Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug, Biological
Study Drugs: Dexamethasone, Carfilzomib, Daratumumab
Study Phase: Phase 2
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2026
Intervention Type: Diagnostic test, Drug, Combination product, Other
Study Drugs: Obinutuzumab, Nivolumab, Prednisone, Lenalidomide, Venetoclax, Ibrutinib
Study Phase: Phase 1
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Short-Course EPOCH - Rituximab in Untreated CD-20+ HIV-Associated Lymphomas
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Drug, Biological
Study Drugs: Rituximab, filgrastim, EPOCH
Study Phase: Phase 2
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
A Study of Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Drug
Study Drugs: TEDD-R, TEDDI-R, Ibrutinib, Cytarabine, Isavuconazole
Study Phase: Phase 2
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Safety and Feasibility of Stem Cell Gene Transfer Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patients Using Peripheral Blood Stem/Progenitor Cells Treated With a Lentivirus Vector-Encoding Multiple Anti-HIV RNAs
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Prednisone, Rituximab, Etoposide, Doxorubicin Hydrochloride, Vincristine Sulfate, Cyclophosphamide, Filgrastim, Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells
Study Phase: Phase 1
View 5 Less Clinical Trials

126 Total Publications

Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 13, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology
Expertise in
19
conditions
Dr. Sharon Savage
Hematology | Oncology

Office

9609 Medical Center Dr, 
Bethesda, MD 
 (4.1 miles away)
240-276-7241
Languages Spoken:
English

Sharon Savage is a Hematologist and an Oncologist in Bethesda, Maryland. Dr. Savage is highly rated in 19 conditions, according to our data. Her top areas of expertise are Dyskeratosis Congenita, Aplastic Anemia, Aase Syndrome, Hormone Replacement Therapy (HRT), and Bone Marrow Transplant.

Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology
Expertise in
13
conditions
Dr. Blanche Alter
Hematology | Oncology

Office

9609 Medical Center Dr Rm 6E452, 
Rockville, MD 
 (11.4 miles away)
240-276-7239
Languages Spoken:
English

Blanche Alter is a Hematologist and an Oncologist in Rockville, Maryland. Dr. Alter is highly rated in 13 conditions, according to our data. Her top areas of expertise are Aase Syndrome, Dyskeratosis Congenita, Aplastic Anemia, Bone Marrow Transplant, and Hormone Replacement Therapy (HRT).

Expertise in
22
conditions
Dr. Craig Kessler
Hematology
Expertise in
22
conditions
Dr. Craig Kessler
Hematology

MedStar Georgetown Cancer Institute At MedStar Georgetown University Hospital

3800 Reservoir Rd NW, 
Washington, DC 
 (5.1 miles away)
202-444-2223
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Craig Kessler is a Hematologist in Washington, Washington, D.c.. Dr. Kessler is highly rated in 22 conditions, according to our data. His top areas of expertise are Blood Clots, Hemophilia A, Acquired Hemophilia, Bone Marrow Aspiration, and Splenectomy.

Frequently Asked Questions about Dr. Mark Roschewski

How do I make an appointment with Dr. Mark Roschewski?

You can book an appointment with Dr. Mark Roschewski by calling their office at 202-782-4950. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mark Roschewski a top-rated expert for B-Cell Lymphoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mark Roschewski is classified as an Elite expert for B-Cell Lymphoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mark Roschewski specialize in?

While Dr. Mark Roschewski is a Hematology, they have specific expertise in B-Cell Lymphoma, Non-Hodgkin Lymphoma, and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Mark Roschewski participate in research or clinical trials?

Yes. Dr. Mark Roschewski has published 126 articles and abstracts on conditions like B-Cell Lymphoma. You can view a list of Dr. Mark Roschewski's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roschewski's expertise for a condition
ConditionClose
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile